Application of cholic acid and fenofibrate in influenza virus infection
Through the combined application of cholic acid and fenofibrate, the infection of H9N2 virus into cells and mice was significantly inhibited, and the prevention and treatment problems of H9N2 subtype avian influenza virus were solved, which improved survival rate and inhibited the lung index caused by the virus. Changes, a new drug combination regimen is provided.
Patent Information
- Application Number
- CN202411152622.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-29
AI Technical Summary
The dual threat of the H9N2 subtype avian influenza virus to poultry and humans is difficult for the prior art to effectively prevent and treat infections caused by them, especially in zoonotic situations.
The combined application of cholic acid and fenofibrate significantly inhibited the infection of H9N2 virus on cells and mice by using fenofibrate and cholic acid in vitro and in vivo experiments, improving survival rate and inhibiting virus-induced infection. pulmonary index changes.
Fenofibrate + cholic acid combination significantly inhibits H9N2 cell infection in vitro, significantly improves the survival rate of mice in vivo, inhibits weight loss and lung index changes, and provides a new prevention and treatment of H9N2 infection. Drug combination regimen.
Smart Images

Figure CN119033794A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biomedical technology, in particular to a new method for preventing and treating H9N2 subtype avian influenza virus infection: the combined use of cholic acid and fenofibrate in influenza virus infection. Background Art
[0002] Avian influenza (AI) is a worldwide disease of poultry caused by avian influenza virus (AIV), with each severe outbreak causing huge economic losses to the poultry industry. The H9N2 subtype of avian influenza virus is a pathogen with significant impact on both poultry and humans. Since 1993, the H9N2 subtype of avian influenza virus has been detected in poultry in multiple provinces in China. Although initially considered to have low pathogenicity to poultry, making it a low priority in animal disease control, its emergence as a zoonotic threat has raised significant public health concerns. The first human infection case was reported in China in 1999, followed by further cases in 2003 and 2013. Serological studies have also shown that poultry workers in China, India, Cambodia, Romania, the United States, Nigeria, and Vietnam have been exposed to H9N2, highlighting its potential threat to human health. The significance of H9N2 is not limited to direct infection. Phylogenetic analysis showed that the H9N2 virus donated internal gene segments to several other influenza strains, resulting in a zoonotic spillover event.
[0003] Cholic acid is one of the major bile acids synthesized by the liver from cholesterol. It is a white crystalline substance that is insoluble in water but soluble in alcohol and acetic acid. The salts of cholic acid are called cholates. Cholic acid and chenodeoxycholic acid are the two major bile acids in humans, present in roughly equal concentrations. Cholic acid is marketed under the trade names Cholbam and Orphacol for the treatment of bile acid synthesis disorders due to single enzyme defects and peroxisomal disorders such as Zellweger syndrome. In the United States, cholic acid has been approved for use in children and adults. The European Union approved Cholbam in September 2013 for the treatment of primary inborn errors of bile acid synthesis in infants, children, adolescents, and adults. Cholic acid is indicated for the treatment of primary inborn errors of bile acid synthesis due to deficiencies of specific enzymes such as steroid 27-hydroxylase, alpha-methylacyl-CoA racemase, and cholesterol 7alpha-hydroxylase. Common side effects include peripheral neuropathy, diarrhea, nausea, acid reflux, esophagitis, jaundice, skin lesions, and fatigue.
[0004] Fenofibrate was first synthesized in 1974 as a derivative of clofibrate and was initially introduced in France under the name procetofen, later renamed fenofibrate in accordance with the World Health Organization International Nonproprietary Name Guidelines. It was patented in 1969 and began to be used for medical purposes in 1975. Fenofibrate is an oral medication that is commonly used to lower bad cholesterol (LDL-C) and increase good cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia (high cholesterol and elevated triglyceride levels). It is also used to lower triglyceride levels to reduce the risk of pancreatitis in patients with severe hypertriglyceridemia. Fenofibrate may also be used for other conditions determined by a medical provider. Common side effects of fenofibrate include liver problems, breathing problems, abdominal pain, muscle problems, and nausea.
[0005] In recent years, the potential therapeutic benefits of the combination of bile acid and fenofibrate in a variety of medical conditions have attracted widespread attention. In terms of mechanism of action, bile acid is a major bile acid that is synthesized by the liver from cholesterol and plays a key role in the digestion and absorption of fats and fat-soluble vitamins. Fenofibrate is a lipid-lowering drug that enhances lipid breakdown by activating peroxisome proliferator-activated receptor α (PPARα). The two drugs have different but complementary mechanisms and may improve lipid metabolism and liver function. The potential therapeutic benefits of combining bile acid and fenofibrate are based on their known effects on viral replication and host immune responses. Studies have shown that bile acids can promote or inhibit viral replication depending on the virus and specific conditions. For example, bile acids have been found to enhance innate antiviral responses and mobilize the host immune system to clear infections in the context of different viruses, such as hepatitis A and B viruses, enteroviruses, and caliciviruses. These findings highlight the importance of exploring the combination of bile acid and fenofibrate for viral therapy, including H9N2 avian influenza virus. Summary of the invention
[0006] The purpose of the present invention is to provide a use of cholic acid and fenofibrate in combination in preventing and treating H9N2 subtype avian influenza virus infection.
[0007] Another object of the present invention is to provide the use of cholic acid and fenofibrate in combination in the preparation of a functional product for preventing and treating H9N2 subtype avian influenza virus infection.
[0008] In order to achieve the above object, the main technical scheme of the present invention is:
[0009] First, the present invention uses mouse mononuclear macrophage Raw264.7 as target cells to infect H9N2, and compares the cell survival rates of the control group, model group, fenofibrate group, bile acid group and fenofibrate+chole acid group.
[0010] Second, the present invention prepared an H9N2 infection mouse model, used fenofibrate, cholic acid, and fenofibrate + cholic acid to treat the infection caused by H9N2, and compared the survival rate, weight loss, and lung index changes of mice in the control group, model group, fenofibrate group, cholic acid group, and fenofibrate + cholic acid group.
[0011] Beneficial effects: The present invention screened out a new combination that can prevent and treat H9N2 infection, namely, fenofibrate + cholic acid combination. The fenofibrate + cholic acid combination can significantly inhibit H9N2 infection of Raw264.7 cells in vitro and can significantly inhibit H9N2 infection of mice in vitro. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 The cell viability was measured by treating Raw264.7 cells infected with H9N2 with fenofibrate, cholic acid, and fenofibrate + cholic acid.
[0013] Figure 2 The survival rate of mice was measured by treating H9N2 infected mice with fenofibrate, cholic acid, and fenofibrate + cholic acid.
[0014] Figure 3 The weight changes of mice were measured by treating H9N2-infected mice with fenofibrate, cholic acid, and fenofibrate + cholic acid.
[0015] Figure 4 The changes in mouse lung index were measured after fenofibrate, cholic acid, and fenofibrate + cholic acid were applied to H9N2-infected mice. DETAILED DESCRIPTION
[0016] In order to enable those skilled in the art to better understand the technical solution of the present invention and implement it, the present invention is further described below in conjunction with specific examples and drawings, but the examples are not intended to limit the present invention. The following test methods and detection methods, unless otherwise specified, are conventional methods; the reagents and raw materials used are commercially available or can be prepared according to literature methods.
[0017] Experimental Materials:
[0018] Drugs and reagents
[0019] Cholic acid was purchased from Aladdin, China, with a molecular formula of C24H35D5O5, a molecular mass of 413.6 g / mol, and a purity of >98%. This product was dissolved in DMSO, prepared into a 10 mmol / L mother solution, and diluted to the corresponding action concentration in proportion for cell tests and animal experiments. Fenofibrate was purchased from Aladdin, China, with a molecular formula of C20H21ClO4, a molecular mass of 360.83 g / mol, and a purity of >99%. This product was dissolved in DMSO at a concentration of 100 mmol / L, and diluted to the corresponding action concentration in proportion for cell tests and animal experiments.
[0020] The H9N2 subtype avian influenza virus originated from this laboratory.
[0021] Raw264.7 (mouse macrophage cell line) was stored in liquid nitrogen by our laboratory.
[0022] 6-8 week old C57BL / 6 mice were purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.
[0023] Example 1: In vitro study of the combined use of cholic acid and fenofibrate on H9N2 subtype avian influenza virus infection in Raw264.7
[0024] Experimental steps:
[0025] Cell recovery: Place the frozen Raw264.7 cells in a 37°C water bath to thaw the cells quickly, sterilize the cryotubes with alcohol and transfer the cells to a 1.5 ml centrifuge tube, centrifuge at 1500 rpm for 5 min, discard the cryoprotectant, add 1 ml phosphate buffered saline (PBS), centrifuge at 1500 rpm for 5 min, discard the PBS, add DMEM medium containing 10% fetal bovine serum, resuspend the cells, transfer to a cell bottle, and culture in a 37°C, 5% carbon dioxide incubator.
[0026] Cell viability detection: Raw264.7 cells in good growth state were inoculated in 96-well plates, 1×105 cells / well. After culturing the cells for 24 hours, the H9N2 subtype avian influenza virus preparation solution with an infection dose MOI=10 was inoculated and placed in a 37°C, 5% carbon dioxide incubator for 3 hours. The virus solution in the cells was aspirated, washed three times with PBS, and fenofibrate, cholic acid, and fenofibrate + cholic acid were added respectively. A control group (only PBS was added, no H9N2 was added), a model group (only H9N2 was added), a fenofibrate group (20mM), cholic acid (5mM), and a fenofibrate (20mM) + cholic acid (5mM) group were set up. Continue to be placed in a 37°C, 5% carbon dioxide incubator for 12h, 24h, and 48h. At the corresponding time, the culture was removed, 20ul CCK-8 solution was added, and the cells were incubated in the incubator for another 1h. The absorbance was measured at 450nm using an ELISA reader, and the cell survival rate was calculated according to the formula in the CCK-8 kit manual. The results were as follows: Figure 1 shown.
[0027] Figure 1 Changes in Raw264.7 cell viability
[0028] Experimental results:
[0029] The results are as follows Figure 1 As shown, compared with the control group, the cell viability of the model group decreased significantly at 12h, 24h and 48h (P<0.01); compared with the model group, the cell viability of the fenofibrate group (20mM), cholic acid (5mM), and fenofibrate (20mM) + cholic acid (5mM) groups at 12h, 24h and 48h was significantly improved (P<0.01), especially the cell viability of the fenofibrate (20mM) + cholic acid (5mM) group increased most significantly, compared with the fenofibrate group (20mM) and cholic acid (5mM) groups, the difference was significant (P<0.01). This shows that the combination of fenofibrate and cholic acid can effectively treat the infection of H9N2 subtype avian influenza virus to Raw264.7.
[0030] Example 2: In vivo study of the combined use of cholic acid and fenofibrate on mice infected with H9N2 subtype avian influenza virus Experimental steps:
[0031] Fifty C57BL / 6 mice aged 6-8 weeks were selected and randomly divided into five groups, 10 mice in each group, including control group (PBS intranasal drops), model group (H9N2 intranasal drops), fenofibrate group (50 mg / kg), cholic acid group (20 mg / kg), and fenofibrate (50 mg / kg) + cholic acid (20 mg / kg). Sodium pentobarbital was diluted to 5 mg / mL with saline and anesthetized by intraperitoneal injection. 50 μl H9N2 (~2.67×103 PFU / ml) was used to drip the model group, fenofibrate group, cholic acid group, and fenofibrate + cholic acid group for intranasal modeling, and the mice in the control group were infected with 50 μl PBS intranasally. 4h after the virus was dripped into the nose, the drug fenofibrate (50mg / kg), cholic acid (20mg / kg), and fenofibrate (50mg / kg) + cholic acid (20mg / kg) were gavaged, and the normal control group and the model group were gavaged with PBS for 5 consecutive days. The weight and survival status of the mice were observed and recorded at the same time every day. The number of mice that survived and the weight changes were observed and recorded for 15 consecutive days. Samples were collected on the 2nd and 4th days, the lesions of the lung tissue were recorded, and the mouse lung index was calculated by weighing, lung index = (mouse lung weight / mouse weight) × 100.
[0032] Experimental results: Figure 2 As shown, the survival rate of mice was monitored for 15 consecutive days. Mice began to die on the third day. The mortality rate of the model group was 48.9% within 15 days after infection, while the mortality rate of the fenofibrate + cholic acid group was 89.2% within 15 days after infection. The survival rate of mice was increased by 40.3%. There was a significant difference between the fenofibrate + cholic acid group and the model group (P<0.001).
[0033] Figure 2 Fenofibrate + cholic acid improves the survival rate of mice infected with H9N2
[0034] like Figure 3 As shown in the figure, during the 15-day monitoring period, the weight of normal mice gradually increased, the weight of mice in the model group continued to decrease, the weight of mice in the bile acid group and the fenofibrate group first decreased and then increased, and by the end of the 15th day, the weight returned to the level at the time of infection, while the weight of mice in the fenofibrate + bile acid group only decreased slightly at the beginning and then returned to normal. There was a significant difference in the weight changes of mice between the fenofibrate + bile acid group and the model group (P<0.001).
[0035] Figure 3 Fenofibrate + bile acid inhibits H9N2-induced weight loss in mice
[0036] H9N2 infection in mice causes pulmonary inflammation, and the lung weight of mice increases over time. Figure 4As shown in the figure, on the 4th day, the lung index of the fenofibrate + bile acid group was significantly lower than that of the model group, and there was a significant difference (P<0.001), while there was no statistical difference in the lung index on the 2nd day.
[0037] Figure 4 Fenofibrate + bile acid reduces lung index in mice
[0038] The above experimental results prove that the present invention has screened a new combination that can prevent and treat H9N2 infection, namely, the combination of fenofibrate + cholic acid. The combination of fenofibrate + cholic acid can significantly inhibit the infection of H9N2 to Raw264.7 cells in vitro and can significantly inhibit the infection of H9N2 to mice in vitro. Therefore, the present invention provides a new drug combination treatment scheme for clinical prevention and treatment of H9N2 infection.
[0039] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.
[0040] The above are only preferred embodiments of the present invention and are not intended to limit the present invention in other forms. Any technician familiar with the profession may use the technical contents disclosed above to change or modify them into equivalent embodiments with equivalent changes and apply them to other fields. However, any simple modification, equivalent change and modification made to the above embodiments based on the technical essence of the present invention without departing from the technical solution of the present invention still falls within the protection scope of the technical solution of the present invention.
Claims
1. The use of cholic acid and fenofibrate in influenza virus infection, characterized in that: The combined use of bile acid and fenofibrate can improve the survival rate of mice infected with H9N2 subtype avian influenza virus, inhibit the weight loss of mice, and reduce the increase of lung index of mice.
2. The use according to claim 1, characterized in that: Combinations of bile acid and fenofibrate include any of the following: a. a preparation in which bile acid and fenofibrate are mixed in a molar ratio of 1:1 to 1:10; b. Cholic acid and fenofibrate are used in combination in the form of separate preparations and are mixed in a molar ratio of 1:1 to 1:10 when used.
3. The use according to claim 1 or 2, characterized in that The combination of bile acid and fenofibrate is achieved by: a. administer bile acid and fenofibrate to experimental animals orally or by injection at appropriate doses and frequencies; b. After infection with H9N2 subtype avian influenza virus, the drug was administered continuously for 5 days.
4. The use according to claim 1 or 2, characterized in that: The combined use of cholic acid and fenofibrate can effectively inhibit the infection of H9N2 subtype avian influenza virus in the mouse mononuclear macrophage cell line Raw264.7 in in vitro experiments.
5. A preparation of cholic acid and fenofibrate for preparing a composition for preventing and treating H9N2 subtype avian influenza virus infection, characterized in that: The preparation comprises cholic acid and fenofibrate, and the molar ratio of cholic acid and fenofibrate is 1:1 to 1:
10.
6. A method for preparing the preparation of bile acid and fenofibrate according to claim 5, characterized in that: The method comprises the following steps: a. Dissolve bile acid in DMSO to prepare a 10 mmol / L stock solution; b. dissolving fenofibrate in DMSO to prepare a 100 mmol / L stock solution; c. According to the desired molar ratio, the cholic acid mother solution and the fenofibrate mother solution are mixed in proportion.
7. A method for treating H9N2 subtype avian influenza virus infection by combining cholic acid and fenofibrate, characterized in that: The program includes: a. Start administration of a combination of cholic acid and fenofibrate within 4 hours of viral infection; b. Administer the drug for 5 consecutive days, administering a combination of bile acid and fenofibrate every day.
8. Use of bile acid and fenofibrate in treating pulmonary inflammation, characterized in that: The combined use of cholic acid and fenofibrate can reduce the lung inflammatory response in mice infected with H9N2 subtype avian influenza virus.
